MYELOMA RESEARCH UNIT PUBLICATIONS 1995-2002

 

1. Joshua DE. (1995) "Immunoglobulins". In, Myeloma: Biology and Management: 3-29. Eds. Malpas J, Bergsagel D and Kyle RA. Oxford University Press

2. Joshua DE, Gibson J. (1995) The place of allogeneic transplantation in myeloma. ABMTR Newsletter July; 10: 7-9.

3. Segelov E, Gibson J, Joshua DE, Kronenberg H. (1995) Primary amyloidosis co-presenting with cervical and massive lymphadenopathy. Leukaemia and Lymphoma. 19:519-520.

4. Brown R, Luo XF, Gibson J, Morley A, Sykes P, Brisco M, Joshua D. (1995) Idiotypic oligonucleotide probes to detect myeloma cells by mRNA in situ hybridization. Br J Haematol 90: 113-118.

5. Joshua DE, Penny R. The biology of plasma cell myeloma. (1995) In: Principles of Medical Biology. Ed. Bittar E, Bittar N. JAI Press Inc. Connecticut, USA.

6. Joshua DE, Brown RD, Luo XF, Gibson J (1996) Circulating clonal lymphocytes in myeloma determined by mRNA in situ hybridization. Blood 88:1125.

7. Joshua DE, Petersen A, Brown RD, Pope B, Snowdon L, Gibson J. (1996) The labelling index of primitive plasma cells determines the clinical behaviour of patients with myelomatosis. British Journal of Haematology 94:76-81.

8. Joshua DE, Gibson J, Brown R. (1996) Myeloma: Biology, prognosis and treatment. Haematology Reviews 9:227-249.

9. Joshua D.E. (1996) Myeloma: New aspects of biology, prognosis and treatment. Pathology 28: 2-7.

10. Forsyth C, Nelson M, Popp H, Snowdon L, Gibson J, Joshua D. (1996) Autologous red cell recovery and relapse of multiple myeloma after bone marrow transplantation: Is this a graft-versus-myeloma effect? Bone Marrow Transplantation 17: 457-459.

11. Joshua DE, Gibson J. Diagnosis and therapy of myeloma. (1996) In: Neoplastic Diseases of the Blood, 3rd ed. Eds. Wiernik, Canellos, Kyle, Schiffer. Churchill Livingstone, NY, 561-583.

12. Pope B, Brown RD, Luo X-F, Gibson J, Joshua D. (1997) Disease progression in patients with multiple myeloma is associated with a concurrent alteration in the expression of both oncogenes and tumour suppressor genes and can be monitored by the oncoprotein phenotype. Leukemia and Lymphoma 25:545-554.

13. Brown RD, Yuen E, Nelson M, Gibson J, Joshua D. (1997) The prognostic significance of T cell receptor β gene rearrangements and idiotype-reactive T cells in multiple myeloma. Leukemia 11:1313-1317.

14. Pope B, Brown RD, Gibson J, Petersen A, Wiley J, Joshua D. (1997) The functional phenotype of the primitive plasma cell in patients with multiple myeloma correlates with the clinical stage. Leukemia and Lymphoma 27:83-91.

15. Joshua D, Penny R, Matthews J, Laidlaw C, Gibson J, Bradstock K, Wolf M, Goldstein D, for the Australian Leukaemia Study Group. (1997) Australian Leukaemia Study Group Myeloma II: a randomized trial of intensive combination chemotherapy with or without interferon in patients with myeloma. British Journal of Haematology 97:38-45.

16. Pope B, Brown R, Gibson J, Joshua D (1997) Plasma cells in the peripheral blood stem cell harvests from patients with multiple myeloma are predominantly polyclonal. Bone Marrow Transplantation 20:205-210.

17. Joshua D, MacCallum S, Gibson J. (1997) The role of alpha interferon in multiple myeloma. Blood Reviews 11: 191-200.

18. Sharland A, Snowdon L, Joshua D, Gibson J, Tiller D. (1997) Hemodialysis: An appropriate therapy in myeloma-induced renal failure. American Journal of Kidney Diseases 30: 786-892.

19. Brown RD, Luo X-F, Gibson J, Brisco M, Sykes P, Morley A, Joshua D. (1998) Longitudinal analysis of circulating myeloma cells detected by allele specific mRNA in situ hybridization. American Journal of Haematology 58:273-277.

20. Joshua DE. (1998) Multiple Myeloma. In: Cancer Facts: A concise text of essential information in oncology. Ed. J Bishop.

21. Brown RD, Pope B, Yuen E, Gibson, Joshua D. (1998) The expression of T cell related costimulatory molecules in multiple myeloma. Leukaemia and Lymphoma 31: 379-384.

22. Joshua DE and Gibson JG. (1998) Epidemiology of plasma cell disorders. In: Myeloma. Ed. J Mehta.

23. Joshua DE. (1998) Prognostic factors in myeloma : tumour burden. In Biology and Management of Myeloma. Ed. J Berenson. Humana Press

24. Pope B, Brown R, Gibson J, Joshua D (1999) The bone marrow plasma cell labelling index by flow cytometry. Communications in Clinical Cytometry 38:286-292.

25. Raitakari M, Brown RD, Sze D, Yuen E, Barrow L, Nelson M, Pope B, Esdale W, Gibson J, Joshua DE. (2000) T-cell expansions in patients with multiple myeloma have a phenotype of cytotoxic T-cells. British Journal of Haematology 110: 203-209.

26. Pope B, Brown RD, Gibson J, Joshua DE. (2000) B7-2 positive myeloma: incidence, clinical characteristics, prognostic significance and implications for immunotherapy. Blood 96:1274-1279.

27. Dyson PG, Horvarth N, Joshua D, Barrow L, van Holst NG, Brown RD, Gibson J, To LB (2000) CD34+ selection of autologous peripheral blood stem cells for transplantation following sequential cycles of high- dose therapy and mobilisation in multiple myeloma. Bone Marrow Transplantation 25:1175-1184.

28. Brown RD, Ho PJ. (2001) Detection of malignant cells in the bone marrow and peripheral blood of patients with multiple myeloma. In: Methods in Molecular Biology Volume 179. Gene Probes: Principles and protocols, Ed M Aquino de Muro and R Rapley, Humana Press, Totowa, NY, USA. 85-91.

29. Ho PJ, Brown RD, Pelka G, Basten A, Gibson J, Joshua DE. (2001) Illegitimate switch recombinations are present in approximately half of primary myeloma tumour, but do not relate to known prognostic indicators. Blood 97: 490-495.

30. Sze DM-Y, Giesajtis G, Brown RD, Raitakari M, Gibson J, Ho PJ, Baxter A, Fazekas de St Groth B, Basten A, Joshua DE (2001) Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8+ CD57+ CD28- compartment. Blood 98: 2817-2827.

31. Brown RD, Pope B, Esdale W, Hart D, Gibson J, Joshua DE. (2001) Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to upregulate CD80 (B7-1) expression after huCD40LT stimulation due to inhibition by TGFb and IL-10. Blood 98: 2992-2998.

32. Joshua D, Pope B, Barrow L, Murray A, Gibson J, Brown R (2002) Phenotyping primitive plasma cells. British Journal of Haematology 117:252.

33. Ho PJ, Brown RD, Basten A, Gibson J, Joshua DE (2002) Response: Illegitimate switch recombinations in promary myeloma tumor. Blood 99: 3072 –3074.

34. Raitakari M, Brown RD, Gibson J, Joshua DE. (2002) T cells in myeloma. Hematological Oncology 21:33-42.

35. Ho PJ, Campbell LJ, Gibson J, Brown R, Joshua D. (2002) The biology and cytogenetics of multiple myeloma. Reviews in Clinical and Experimental Hematology 6.3: 276-300.

36. Sze DM-Y, Brown RD, Yang S, Gibson J, Ho PJ, Fazekas de St Groth, Basten A, Joshua DE. (2003) Prediction of high affinity class -restricted multiple myeloma idiotype peptide epitopes. Leukemia and Lymphoma 44:1557-1568.

37. Sze DM-Y, Brown RD, Yuen E, Gibson J, Ho PJ, Raitakari M, Basten A, Joshua DE, Fazekas de St Groth (2003). Clonal cytotoxic T cells in myeloma. Leukemia and Lymphoma 44:1667-1674.

38. Barrow L, Brown RD, Murray A, Pope B, Gibson J, Hart D, Joshua D. (2003) CMRF44+ dendritic cells from peripheral blood stem cell harvests as potential cellular vectors for idiotype vaccination. Leukemia and Lymphoma 44:2217-2122

39. Brown RD, Murray A, Pope B, Sze D, Gibson J, Ho PJ, Joshua DE. (2004) B7+ T cells im myeloma: and acquired marker of prior chronic antigen presentation and unreponsiveness. Leukemia and Lymphoma 45:363-371.

40. Brown R, Murray A, Pope B, Sze DM, Gibson J, Ho PJ, Hart D, Joshua DE. (2004) Either IL-12 or interferon-gcan correct the dendritic cell defect induced by TGFb1 in patients with myeloma. British Journal of Haematology 125:743-748.

41. Joshua DE, Ho PJ, Gibson J, Brown RD. (2004) The immune system in myeloma. In: Multiple myeloma and related disorders. Ed Gharton G, Durie B, Samson D. p29-45.

42. Horvath N, Hahn U, Joshua D, Dyson P, Gibson J, Stevens J, Rawling T, Barrow L, Brown R, Stephens S, Gower G, Norman J, Mills B, To LB. (2004) Long-term follow-up of sequential mobilization and autologous tranplantation with CD34 selected cells in multiple myeloma: a multi-modality approach. Internal Medicine Journal 34:167-175.

43. Turtle CJ, Brown RD, Joshua DE, Hart DN. (2004). DC in multiple myeloma immunotherapy. Cytotherapy 6:128-37.

44. Durie BG, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoro M, Child JA, Comenzo R, Djulbegovic B, Fantl D, Gahrton G, Harousseau JL, Hungria V, Joshua D, Ludwig H, Mehta J, Morales AR, Morgan G, Nouel A, Oken M, Powles R, Roodman D, Miguel JS, Shimizu K, Singhal S, Sirohi B, Sonneveld P, Tricot G, Ness BV. (2004) Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematology Journal 53:285.

45. Durie BG, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoro M, Child JA, Comenzo R, Djulbegovic B, Fantl D, Gahrton G, Harousseau JL, Hungria V, Joshua D, Ludwig H, Mehta J, Morales AR, Morgan G, Nouel A, Oken M, Powles R, Roodman D, San Miguel J, Shimizu K, Singhal S, Sirohi B, Sonneveld P, Tricot G, Van Ness B. (2004) Scientific Advisors of the International Myeloma Foundation. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematology Journal. 4:379-98.

46. Ho PJ, Gibson J, Joshua D. (2004) The treatment of multiple myeloma: current management and new approaches. American Journal of Cancer 3:47-66.

47. Brown RD, Ho PJ (2004) Multiple myeloma: Methods and Protocols. Methods in Molecular Medicine. Ed Brown RD, Ho PJ, Humana Press. (in press).

48. Brown RD, Ho PJ (2004) Detection of myeloma cells by in situ hybridisation. In: Multiple myeloma: Methods and Protocols. Methods in Molecular Medicine. Ed Brown RD, Ho PJ, Humana Press. (in press).

49. Joshua DE, Brown RD, Ho PJ. Multiple myeloma: challenges and opportunities. Multiple myeloma: Methods and Protocols. Methods in Molecular Medicine. Ed Brown RD, Ho PJ, Humana Press. (in press).

50. Yuen E, Brown RD. Southern blotting of IgH rearrangements in B cell disorders. Multiple myeloma: Methods and Protocols. Methods in Molecular Medicine. Ed Brown RD, Ho PJ, Humana Press. (in press).

51. Gibson J, Ho PJ, Joshua DE. (2004) Evolving transplant options for multiple myeloma -autologous and non-myeloablative allogeneic. Transplant Proceedings. (In press ).

52. Joshua DE (2004) Tumour burden. In: Current Clinical Oncology: Biology and Management of Multiple Myeloma. Ed Berenson J. Humana Press, Totowa, NJ, USA (in press)